These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12052652)

  • 1. In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development.
    Atterwill CK; Wing MG
    Toxicol Lett; 2002 Feb; 127(1-3):143-51. PubMed ID: 12052652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development.
    Atterwill CK; Wing MG
    Altern Lab Anim; 2000; 28(6):857-67. PubMed ID: 11105205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ECVAM and pharmaceuticals.
    Vanparys P
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():221-3. PubMed ID: 12513680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of investigative molecular toxicology in early stage drug development.
    Gross CJ; Kramer JA
    Expert Opin Drug Saf; 2003 Mar; 2(2):147-59. PubMed ID: 12904115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicology testing in drug discovery and development.
    Dorato MA; Buckley LA
    Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From in vivo to in vitro/in silico ADME: progress and challenges.
    Van de Waterbeemd H
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):1-4. PubMed ID: 16922647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.
    Theil FP; Guentert TW; Haddad S; Poulin P
    Toxicol Lett; 2003 Feb; 138(1-2):29-49. PubMed ID: 12559691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.
    Balani SK; Miwa GT; Gan LS; Wu JT; Lee FW
    Curr Top Med Chem; 2005; 5(11):1033-8. PubMed ID: 16181128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools.
    Willmann S; Lippert J; Schmitt W
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):159-68. PubMed ID: 16922658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotoxicity screening: the slow march to the future.
    Walmsley RM
    Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):261-8. PubMed ID: 16922641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hit discovery and hit-to-lead approaches.
    Keseru GM; Makara GM
    Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systems-ADME/Tox: resources and network approaches.
    Ekins S
    J Pharmacol Toxicol Methods; 2006; 53(1):38-66. PubMed ID: 16054403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging technologies and challenges for better and safer drugs.
    Theodosiou M; Amir-Aslani A; Mégarbane B
    Biotechnol Lett; 2014 Apr; 36(4):677-84. PubMed ID: 24243233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.
    Tsaioun K; Blaauboer BJ; Hartung T
    ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can preclinical drug development help to predict adverse events in clinical trials?
    Chi LH; Burrows AD; Anderson RL
    Drug Discov Today; 2022 Jan; 27(1):257-268. PubMed ID: 34469805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of high throughput technology for the screening of natural products.
    Mishra KP; Ganju L; Sairam M; Banerjee PK; Sawhney RC
    Biomed Pharmacother; 2008 Feb; 62(2):94-8. PubMed ID: 17692498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach.
    Ebbels TM; Keun HC; Beckonert OP; Bollard ME; Lindon JC; Holmes E; Nicholson JK
    J Proteome Res; 2007 Nov; 6(11):4407-22. PubMed ID: 17915905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A flexible approach for optimising in silico ADME/Tox characterisation of lead candidates.
    Bidault Y
    Expert Opin Drug Metab Toxicol; 2006 Feb; 2(1):157-68. PubMed ID: 16863475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.